• Alembic Pharma’s consolidated revenues for the quarter ended December (Q4FY22) were up 11% quarter-on-quarter (QoQ). On a year-on-year (YoY) basis, it witnessed a growth of 9%.
  • Its expenses for the quarter were up 27% QoQ and 37% YoY.
  • While the company reported a 80% QoQ net profit decline, the same was down by 86% on a YoY basis.
  • The earnings per share (EPS) of Alembic Pharma stood at 1.8 during Q4FY22.

Alembic Pharma’s Financial Statements for Q4FY22:

(Rs, crores) Q4FY21 Q3FY22 Q4FY22 QoQ (%) YoY (%)
Total Income 1,306 1,287 1,426 11% 9%
Total Expenses 1,014 1,090 1,385 27% 37%
Profit before tax 292 197 41 -79% -86%
Tax 54 32 -2 - -
Profit after tax 251 176 35 -80% -86%
Earnings per share 12.8 9.0 1.8    

Data Source: BSE, Company announcements

Want to keep a tab on Indian listed companies? Open an account and get daily stock research updates from Kotak Securities.

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results